Sudeep Pharma’s Q1 operating margin beat Healthcare peers by 10.19 points
The consolidated quarter had operating profit above other income, while management highlighted Premix and Encapsulation growth and progress on expansion projects.
Filed 04 Aug 2026, 17:58 IST · after market close · Sudeep Pharma Ltd (SUDEEPPHRM)
Key takeaways
- Consolidated Q1FY27 operating margin of 34.69% was 10.19 percentage points above the median for 34 reported Healthcare peers.
- Operating profit of Rs 54.91 cr exceeded other income of Rs 5.45 cr, limiting the quarter’s reliance on non-operating income.
- Management said the Greenfield project carries approximately Rs 150 cr of capex and is designed for 51,200 MT of annual capacity.
Price around the results
A high-margin quarter against Healthcare peers
Sudeep Pharma’s consolidated operating margin was 34.69%, 10.19 percentage points above the median among 34 Healthcare peers that have reported. Operating profit of Rs 54.91 cr was substantially larger than other income of Rs 5.45 cr, so reported profitability was not driven mainly by non-operating income. Net profit was Rs 40.59 cr after a 25.24% tax rate.
Premix and Encapsulation supported the quarter
Management said the Specialty Ingredients business delivered a strong quarter, led by growth in its Premix and Encapsulation portfolios. The company also said the quarter faced geopolitical uncertainty, supply-chain disruption, intermittent gas constraints and elevated logistics costs. It added that higher energy costs affected European industrial activity and subdued demand in some NSS customer segments.
Expansion remains the main execution marker
Management said regulatory approvals and customer qualification work for the Greenfield expansion were progressing as planned. The presentation identifies approximately Rs 150 cr of capex and 51,200 MT of annual capacity for the Nandesari project. Management said SAM Phase 1 is planned for commissioning by March 2027 with a 25,000 MT capacity target, while existing pharma iron phosphate capacity has been upgraded to produce 5,000 MT of battery-grade material.
Results were filed after market close
The consolidated results were filed after market close, so the post-results stock reaction is not yet part of this note. There is also no prior-quarter or year-ago comparison in the reported set, making the peer-margin comparison the clearest available benchmark for Q1FY27.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹158 cr |
| Other income | ₹5 cr |
| Expenses | ₹103 cr |
| Operating profit | ₹55 cr |
| Operating margin (%) | 34.69% |
| Interest | ₹2 cr |
| Depreciation | ₹4 cr |
| Profit before tax | ₹54 cr |
| Tax | ₹14 cr |
| Net profit | ₹41 cr |
| EPS (₹) | ₹3.59 |
Operating margin of 34.69% compares with a Healthcare sector median of 24.50% across 34 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The Specialty Ingredients business delivered strong quarterly performance through growth in Premix and Encapsulation.
- SAM made progress during the quarter, including two additional strategic MoUs and an expanding qualification pipeline.
Guidance & outlook
- The Greenfield expansion remains on track, with regulatory approvals and customer qualification activities progressing as planned.
- SAM Phase 1 is planned for commissioning by March 2027, with Phase 2 planning already initiated.
- The company expects its NSS integration roadmap to drive efficiencies, strengthen customer relationships and enhance medium-term profitability.
Expansion
- The Greenfield project in Nandesari has approximately INR 150 crore of capex and annual capacity of 51,200 MT.
- SAM Phase 1 has estimated project completion by March 2027 and targets 25,000 MT of capacity.
- Existing pharma iron phosphate capacity has been upgraded to produce 5,000 MT of battery-grade material.
New initiatives
- The company is pursuing operational excellence, manufacturing efficiency and disciplined cost-management initiatives.
- Planning activities for SAM Phase 2 are already underway.
- The company is executing an NSS integration roadmap across commercial, supply chain, procurement and operational functions.
- The company is integrating recently acquired entities and continuing to evaluate inorganic growth opportunities.
Competition
- The company positions itself as a reliable non-Chinese supplier of battery-grade iron phosphate PCAM.
Problems & risks
- The quarter faced geopolitical uncertainties, supply chain disruptions, intermittent gas constraints and elevated logistics costs.
- Elevated energy costs weakened European industrial activity and subdued demand in certain NSS customer segments.
- Continued container shortages affected key trade routes during Q1 FY27.
What to watch
- Whether consolidated operating margin holds above 34.69% in the next reported quarter.
- Progress on SAM Phase 1 against the company’s March 2027 commissioning plan and 25,000 MT target.
- Regulatory approvals and customer qualification for the Greenfield project ahead of its planned 51,200 MT annual capacity.